Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. - Wikidata - awgldk - TriplyDB

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

http://www.wikidata.org/entity/Q34249714

about

CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models Emerging drugs for the treatment of knee osteoarthritis.Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.

P2860

Q35167204-6E9BE78A-64A1-4E7D-ADCA-62B376647EB6 Q38417521-32C2D1E8-E3BF-4485-8552-7A2126936EA7 Q38733892-455471CE-E902-4966-A65D-BEC82956B8B0 Q39343333-29D1AB26-9879-4840-B255-3F9741C2B8A9 Q47140952-2E1D5594-E385-4447-A2AD-A5EDCC8C9992

P2860

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

http://www.wikidata.org/entity/Q34249714

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@ast

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@en

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@nl

type

label

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@ast

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@en

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@nl

prefLabel

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@ast

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@en

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@nl

P1433

Q34249714-68517E6C-EB02-47A4-B316-DAFFF6C67068

P1476

Q34249714-9AC8A390-0D78-413A-B30A-3A5FCFC6F52F

P2093

Q34249714-39E6303C-DE74-469A-A855-983FD96A0E97

Q34249714-3FE6EB43-3064-4EB3-9229-D3DC0BC59936

Q34249714-44674CDF-24B8-430C-B275-98808A3A0854

Q34249714-8C1AF93F-0CD7-4243-AF5F-0ADEA9337A24

Q34249714-F751E223-2C3F-4056-82C8-1C30B02EECC4

P2860

Q34249714-015CA9D9-C274-414D-B267-4DF05BFCB0E2

Q34249714-19C5BCBB-7EB0-4C5B-ACE3-503F1AA145EB

Q34249714-1FDD2E91-F144-4E0E-A765-CFA449CD2FC6

Q34249714-256AD9C1-8FF1-4B9B-9A76-852992821058

Q34249714-344E143D-3CBD-4803-B70F-8E9C5D4D550C

Q34249714-35F8A9F9-E1F4-4DE0-A34A-5A9A93758197

Q34249714-59FF7278-FB84-4FBC-A677-CB37ACFA4F39

Q34249714-76A9B281-DF9B-4CED-9A37-9ED6DDDA7FA1

Q34249714-76B4704D-D2DA-4627-8B1D-30AE341A77AC

Q34249714-9FCD53F5-382A-4593-8FF8-EE91523730CE

P304

Q34249714-0C43E732-8D23-4CD9-BA62-D683C5860D72

P31

Q34249714-EE3472C5-B255-45E6-9F00-6E2503F3A635

P356

Q34249714-4FF09E95-0765-436B-915D-DB989369324B

P407

Q34249714-E25926EA-E948-4D42-B3A3-5364C2CF8506

P433

Q34249714-9F635579-39A9-47D0-8037-0A123915017A

P478

Q34249714-A192BB73-AAA8-4285-A6BA-B3E50DD673B2

P50

Q34249714-7E1FC656-B840-4A86-9E85-E0A14C0F7AD4

P577

Q34249714-DBF8AFD7-0D7C-4D8D-8FC4-B7DA2267D5EA

P698

Q34249714-6A47EB8E-904D-41A8-824B-43A05DEA17C4

P932

Q34249714-366088D3-A4FA-464C-8532-4A5D2301AC31

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Comparative impact on prostano ...... ti-inflammatory drug CG100649.

@en

P2093

G A Fitzgerald

http://www.w3.org/2001/XMLSchema#string

J A Lawson

http://www.w3.org/2001/XMLSchema#string

K J Propert

http://www.w3.org/2001/XMLSchema#string

L Cen

http://www.w3.org/2001/XMLSchema#string

N Alamuddin

http://www.w3.org/2001/XMLSchema#string

P2860

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs

COX-2 inhibitors and cardiovascular risk.

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

The translational therapeutics of prostaglandin inhibition in atherothrombosis.

Emotion recollected in tranquility: lessons learned from the COX-2 saga.

Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.

Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure.

Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.

P304

986-993

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2012.3

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22278334

http://www.w3.org/2001/XMLSchema#string

P932

3740579

http://www.w3.org/2001/XMLSchema#string